Utilidata | $60,300,000 | (Apr 30, 2025)
Near Space Labs | $20,000,000 | (Apr 30, 2025)
HealthPlan Data Solutions | $15,000,000 | (Apr 30, 2025)
Vicebio
United Kingdom
- Londres, Angleterre, Royaume-Uni
- 24/09/2024
- Series B
- $100,000,000
Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.
- Industry Biotechnology Research
- Website https://vicebio.com/
- LinkedIn https://www.linkedin.com/company/vicebio/
Related People
Emmanuel HanonFounder
Belgium -
Brussels Metropolitan Area
Research & Development leader, C-level Executive, with more than 20 years experience at GSK, last 7 years running the global vaccines RD for GSK. Led the discovery and development of five major Vaccines : Quadrivalent Influenza (Fluarix and Flulaval Quadrivalent), Shingles (Shingrix), Malaria (Mosquirix), RSV older adult, and MenABCWY 5-in-1 Vaccines.
Broad functional leadership experience includes R&D, medical, clinical, regulatory, technical CMC, manufacturing and quality operations. Expert in Immunology, Microbiology, and Vaccinology
Growers Edge | $25,000,000 | (Apr 30, 2025)
Blooming Health | $26,000,000 | (Apr 30, 2025)
KiwiPay | $10,000,000 | (Apr 30, 2025)
GORGIE | $24,500,000 | (Apr 30, 2025)
VSORA | $46,000,000 | (Apr 30, 2025)
Villa | $40,000,000 | (Apr 30, 2025)
Dex | $3,100,000 | (Apr 30, 2025)
Basil Systems | $11,500,000 | (Apr 30, 2025)